325 related articles for article (PubMed ID: 30796165)
1. Early Phase I Study of a
Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Imaging of Tumor PD-L1 Expression Using [
Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
[TBL] [Abstract][Full Text] [Related]
3. Inter-rater and intra-rater agreement of [
Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intraobserver agreement of the quantitative assessment of [
Hughes DJ; Chand G; Goh V; Cook GJR
EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract][Full Text] [Related]
6. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
7. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
[No Abstract] [Full Text] [Related]
8. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
9. Study of
Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
[TBL] [Abstract][Full Text] [Related]
10.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
11. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
12. The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions.
Ergün EL; Kara PO; Gedik GK; Kars A; Türker A; Caner B
Ann Nucl Med; 2007 Jul; 21(5):275-83. PubMed ID: 17634845
[TBL] [Abstract][Full Text] [Related]
13. Preclinical development and characterisation of
Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
15.
Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
[TBL] [Abstract][Full Text] [Related]
16. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
17. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
18. Development, Characterization, and Radiation Dosimetry Studies of
Kim J; Donnelly DJ; Tran T; Pena A; Shorts AO; Petrone TV; Zhang Y; Boy KM; Scola PM; Tenney DJ; Poss MA; Soars MG; Bonacorsi SJ; Cole EL; Grootendorst DJ; Chow PL; Meanwell NA; Du S
Mol Imaging Biol; 2024 Apr; 26(2):301-309. PubMed ID: 38123744
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry estimation and preliminary clinical application of [
Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
[TBL] [Abstract][Full Text] [Related]
20. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
